# OnCo record barbican (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/barbican/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "barbican", "NCT05498896" ;
  schema:name "BARBICAN"@en ;
  schema:description "BARBICAN, run from Barts in London, tests whether adding the AKT-blocking tablet ipatasertib to pre-operative chemotherapy and atezolizumab makes more triple-negative tumours disappear. It has finished recruiting 146 women and is due to report in 2026."@en ;
  schema:url <https://onco.cc/trials/barbican/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05498896> ;
  onco:status "active" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/akt/> ;
  onco:drugs <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/pcr/> ;
  onco:trials <https://onco.cc/trials/ipatunity130/>, <https://onco.cc/trials/neotrip/>, <https://onco.cc/trials/nct03997123/> .